|Title||Design and development of high affinity dual anticancer peptide-inhibitors against p53-MDM2/X interaction.|
|Publication Type||Journal Article|
|Year of Publication||2020|
|Authors||Rasafar N, Barzegar A, Aghdam EMehdizadeh|
|Date Published||2020 Mar 15|
|Keywords||Antineoplastic Agents, Drug Evaluation, Preclinical, Humans, Protein Binding, Proto-Oncogene Proteins c-mdm2, Structure-Activity Relationship, Tumor Suppressor Protein p53|
AIMS: Inhibition of P53-MDM2/X interaction is known as an effective cancer therapy strategy. In this regard, pDI peptide was introduced previously with the potential of targeting MDM2. In this research, the large-scale peptide mutation screening was used to achieve the best sequence of pDI with the highest affinity for inhibition activity against MDM2/X.
MAIN METHODS: Three mutant peptides of pDI as dual inhibitor peptides including single mutations of pDIm/4W, pDIm/11M and double mutations of pDIdm/4W11M were presented with the high affinities to inhibit both MDM2/X. The selected mutants were then evaluated comprehensively to confirm their ability as potent MDM2/X inhibitors, using a theoretical simulation approach.
KEY FINDINGS: MD simulations analyses confirmed their dual inhibition potential against both MDM2/X interactions with p53 protein. The developed pDIm and mainly pDIdm peptides showed stable conformations over the simulation time with conserved secondary structure and effective interaction with MDM2/X by physical binding such as hydrogen bonding. Besides, umbrella sampling free energy calculation indicated higher binding energy, ΔG, of pDIm-MDM2/X and pDIdm-MDM2/X compared to pDI-MDM2/X.
SIGNIFICANCE: The optimized and improved mutant pDI, pDIdm, with more effective ΔG values of -30 and -25 kcal/mol to MDMX and MDM2, respectively, is recommended as a promising anticancer agent and suitable candidate for experimental evaluations.
|Alternate Journal||Life Sci|